Check out the newest antimicrobials and cell biology reagents below.

Antimicrobials

Ethambutol DiHCl (E005) - anti-tubercular antibiotic, inhibits cell wall synthesis in Mycobacterium species.

Cefmetazole sodium (C052) - broad spectrum, second generation cephalosporin. 

Cefotetan disodium (C117) - cephamycin antibiotic, especially effective against anaerobic bacteria. 

Thiostrepton, Ultrapure (T042) - cyclic peptide antibiotic, inhibits protein synthesis. Thiostrepton, ultrapure is >98.0% pure. 

Cell Biology Reagents

Avermectin B1a, EvoPure® (A063) - Macrocycline lactone used in agricultural and veterinary applications as an insecticide and anti-parasitic agent, respectively.

Omeprazole (O011) - Antacid compound which inhibits enzymes that aid in gastric acid secretion.

Paclitaxel (P045) - Anti-tumor agent active in the G2/M growth phase during mitosis.

Zymosan A (Z001) - Stimulates TLR-2, an immunologic receptor which recognizes surface proteins in bacteria.

Click here to see full list of products 

Researchers from the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research today unveiled the first-ever antimicrobial hydrogel that can break apart biofilms and destroy multidrug-resistant superbugs upon contact. Tests have demonstrated the effectiveness of this novel synthetic material in eliminating various types of bacteria and fungi that are leading causes of microbial infections, and preventing them from developing antibiotic resistance. This discovery may be used in wound healing, medical device and contact lens coating, skin infection treatment and dental fillings.

IBN Executive Director Professor Jackie Y. Ying said, “As a multidisciplinary research institute, IBN believes that effective solutions for complex healthcare problems can only emerge when different fields of expertise come together. Our longstanding partnership with IBM reflects the collaborative creativity across multiple platforms that we aim to foster with leading institutions and organizations. By combining IBN's biomaterials expertise and IBM’s experience in polymer chemistry, we were able to pioneer the development of a new nanomaterial that can improve medical treatment and help to save lives.”

Dr Yi-Yan Yang, Group Leader at IBN said, “The mutations of bacteria and fungi, and misuse of antibiotics have complicated the treatment of microbial infections in recent years. Our lab is focused on developing effective antimicrobial therapy using inexpensive, biodegradable and biocompatible polymer material. With this new advance, we are able to target the most common and challenging bacterial and fungal diseases, and adapt our polymers for a broad range of applications to combat microbial infections.”

More than 80% of all human microbial infections are related to biofilm. This is particularly challenging for infections associated with the use of medical equipment and devices. Biofilms are microbial cells that can easily colonize on almost any tissue or surface. They contribute significantly to hospital-acquired infections, which are among the top five leading causes of death in the United States and account for US$11 billion in healthcare spending each year.